SRR12202425
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.380
- MITOTIC_SPINDLE+0.320
- PROTEIN_SECRETION+0.300
- SPERMATOGENESIS+0.210
- DNA_REPAIR+0.200
- MYC_TARGETS_V1+0.190
- HEME_METABOLISM+0.140
- OXIDATIVE_PHOSPHORYLATION+0.130
- FATTY_ACID_METABOLISM+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.490
- HEDGEHOG_SIGNALING-0.360
- APICAL_SURFACE-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.290
- KRAS_SIGNALING_DN-0.290
- ANGIOGENESIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3021 | Med | Medulloblastoma | 0.919 |
| 2 | SRR23303743 | — | — | 0.918 |
| 3 | 20040104.LumB | — | B | 0.917 |
| 4 | MDT-AP-3402 | Med | Medulloblastoma | 0.907 |
| 5 | SRR1797285 | — | cohortSC | 0.905 |
| 6 | SRR1797279 | — | cohortSC | 0.904 |
| 7 | MNG1070 | — | — | 0.903 |
| 8 | SRR1797277 | — | cohortSC | 0.901 |
| 9 | SRR1797245 | — | cohortSC | 0.900 |
| 10 | BS_CHDGRYHJ | medulloblastoma | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |